Articles On Anatara Lifesciences (ASX:ANR)

Anatara Lifesciences (ASX: ANR) has reported that recruitment for Stage 2 of its pivotal GaRP (Gastrointestinal ReProgramming) trial for the treatment of irritable bowel syndrome (IBS) is proceeding well and remains on budget. The company h...

Recruitment is advancing for Stage 2 of Anatara Lifesciences’ (ASX: ANR) pivotal gastrointestinal reprogramming (GaRP) trial to treat irritable bowel syndrome (IBS). The five trial sites in Melbourne, Sydney and Brisbane have received more...

Anatara Lifesciences (ASX: ANR) has initiated Stage 2 of a Phase II gastrointestinal re-programming (GaRP) trial to treat patients with irritable bowel syndrome (IBS). The milestone follows “highly encouraging” findings from Stage 1 of the...

Steve Lydeamore’s advice to biotech peers seeking to do business with the US military is to be armed with a high knowledge readiness level (KRL) when it comes to interpreting acronyms such as … KRL. The head of traveller’s diarrhoea fighter...

Anatara Lifesciences (ASX:ANR) has announced that it has received firm commitments for a placement to raise a total of $1 million before costs.

Irritable bowel syndrome (IBS) is well-named, many sufferers are unaware of why they are feeling so uncomfortable and it can lead to many years of unhappiness. It is estimated that between 5% to 10% of the world’s population may currently b...

Anatara Lifesciences (ASX: ANR) is inviting members of the public to register their interest in Stage 2 of a pivotal Phase II Australian clinical trial of their gastrointestinal reprogramming (GaRP) product in the treatment of irritable bow...

The ASX has ended the week lower, down 0.55pc on Friday Healthcare Sector remains defiant  Small caps led by medtech names and Lake Johnston lithium hunters   The fickle Aussie sharemarket has given back on Friday all that it has made thi...

AVITA jumps after providing bullish guidance Anatara up after holding AGM this morning Imugene doses first patient in its Phase 1b clinical trial using azer-cel   AVITA up on bullish sales forecast Regenerative medicine biotech, AVITA Med...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

Anatara Lifesciences (ASX:ANR) has announced further data from the interim analysis of stage one of its Gastrointestinal ReProgramming (GaRP) trial for irritable bowel syndrome.

Anatara to progress in Phase 1/2 clinical trial of bowel syndrome Noxopharm to present data at conference for pancreatic cancer   Anatara Lifesciences (ASX:ANR) surged 11% this morning after announcing positive results from Stage 1 of its...

Benchmark index settles almost -0.6% lower on Tuesday All sectors bar Healthcare and Financials in the red Small caps led by NickelSearch and Biotron A positive lead from Wall Street overnight didn’t sell well on local markets, which were...

Anatara Lifesciences (ASX:ANR) has provided an update on the Gastrointestinal ReProgramming trial for irritable bowel syndrome.

The ASX set to fall on Tuesday, tracking movements on Wall Street Binance CEO charged by the US SEC The RBA will hand down its rates decision today   After three straight sessions of gains, Aussie shares are set to open lower as US stocks...

Anatara Life’s (ANR) 200-patient Gastrointestinal ReProgramming (GaRP) trial gains momentum, with enrolments back on track after ANR’s festive season break The company expects to finish recruitment for the first phase of the trial early...

Volpara’s share price rose 10% this morning after the US FDA finalised a new federal regulation on breast density language Anatara’s provides strong update on Irritable Bowel Syndrome trial   Volpara Health (ASX:VHT) rose 9% this morning...

Anatara Lifesciences (ANR) enters into a trading halt while it plans a capital raiseThe company has not yet announced how much it plans to raise nor how it will spend the moneyThe specialist life sciences company expects to remain in the tr...

It’s Wednesday. Hump day. And boy-oh-boy are some of us feeling well and truly humped as it draws to a close, so it’s time to pause, reflect and relax – as is tradition (because we’ve been doing this for a week, and so far only one person h...

Anatara Lifesciences (ANR) receives ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome (IBS) and psychological functioning trials The expansion comes after the company was facing a significant screening failure...

Microba will progress to preclinical trial in 2022 Anatara’s CEO resigns Newly listed Microba Life Sciences (ASX:MAP) has identified three therapeutic leads for the company’s immuno-oncology program, significantly earlier than expected. T...

The ASX 200 Health Index (XHJ) has dropped by almost 5% at the time of writing, compared to the broader index which is down by 0.20%. Healthcare giant and blood specialist, CSL (ASX:CSL), which makes up a large part of the ASX Healthcare in...

Microba Life Sciences will work with Anatara Life Sciences (ASX:ANR) to complete microbiome analysis for a therapeutic treatment for sufferers of IBS-D.

Summary  ASX-listed animal health business Apiam disclosed the acquisition of Golden Plains Group to expand its market presence. Anatara Lifesciences completed a challening experiment in weaner piglets with its BONIFF (bromelain-based...

The Anatara Lifesciences Ltd (ASX: ANR) share price is one of the best performers on the ASX today. This comes after the company announced it has secured an Australian patent for its animal health product, Detach and provided an update on...

Source: Krisana Antharith, Shutterstock While the benchmark index, ASX200 was marginally down, two Australian healthcare penny stocks were on the move on the back of important announcements. Specialty pharmaceutical company Mayne Pharma Gr...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

A quick wrap of the ASX’s key winners and losers on Friday, August 21. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 830 stocks rose, 552 declined and 7...

A quick wrap of the ASX’s key winners and losers on Tuesday, August 18. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 888 stocks rose, 534 declined and...

Nearly two years of pain for Factor Therapeutics (ASX:FTT) shareholders could be over soon with the company signing a term sheet to negotiate a potential acquisition. In 2018, Factor was trying to commercialise a wound-dressing drug, which...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Cochlear’s...

Small caps can make investors very wealthy, but can they do the same for our nation? Australia’s main sovereign wealth fund, Future Fund, was established in 2006 and manages $168bn in assets. According to the Sovereign Wealth Institute this...

Gastrointestinal diseases are among the most inconvenient types of illnesses to have, and not just because they may have you running to the loo every five minutes. The field covers many diseases like Irritable Bowel Syndrome (IBS), Crohn’s...

Got 90 seconds? Then listen to Anatara Lifesciences  CEO Steven Lydeamore tell us about his company’s gastrointestinal health products and upcoming newsflow. Anatara Lifesciences (ASX:ANR) is developing and commercialising a range of gastro...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small cap health stocks, 51 saw their share prices fall, 73 improved and 15 were flat. The top mover was G Medical (ASX:GMV), which has finally begu...

The European Commission has granted Orphan drug status for Alterity Therapeutics’ (ASX:ATH) lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). That gives Alterity 10 years of market exclusivity in the European Union...

Who needs human companionship when we have pets? They’re loyal, always happy to see you and won’t divorce you and take half your stuff. According to the RSPCA, Australia is home to 24 million domestic animals. Dogs were present in 38 per ce...

At first glance, the health and life sciences sector on the ASX appears vibrant. There are several success stories, like Viralytics and Sirtex which were both acquired last year. There are other companies that have grown from microcaps to l...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim interviews Kate Quirke, Group Managing Director o...

The 10th Annual Australian Microcap Investment Conference will be held on Tuesday 22 October 2019 over two days at the Sofitel Melbourne on Collins. The Conference is Australia’s largest and most comprehensive emerging company investment ev...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Queenstown is known as the adventure capital of the world. It attracts over three million people per year to experience the world-class ski runs, zip-line riding, white water rafting, sky diving and is, of course, famous for manufacturing t...

Anatara Lifesciences: Anatara can still partner Detach By Pitt Street Research On 14 June 2019, Anatara Lifesciences ((ANR)) announced that it would retain exclusive rights to Detach for livestock and horses, as Zoetis, Anatara’s former par...

Penny stocks are those common stocks whose share price is less than $1. In other words, Penny stocks trade at low market capitalization apart from having a very low stock price. Stocks with market capitalization under $300 million are consi...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. Stocks highlighted in yel...